TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02673684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental NSS
Description: 5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSS
Description: (5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
Study: NCT02119390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff-delivered intervention sessions
Description: In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Questionnaire
Description: Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.

Intervention type: OTHER
Group type: OTHER
Intervention: Demographic Questionnaire
Description: Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
Study: NCT03890770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study: NCT03020823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02952027

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Use-recording, patient-reminder alarm for incentive spirometry
Study: NCT04103632

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EVH test
Description: * Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement
Study: NCT02631863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid
Description: Aminolaevulinic acid with illumination
Study: NCT02119390

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
Study: NCT02409342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Study: NCT04029103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knowledge, behaviour, self efficacy
Description: Knowledge, behavior and self-efficacy of both groups were measured before and after the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knowledge, behaviour, self efficacy
Description: Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
Study: NCT03006692

Intervention type: OTHER
Intervention: With arterial blood gas, parameters not being normal can be corrected
Description: If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
Study: NCT02349750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch injury
Description: ESI using No.8 neonatal feeding tube
Study: NCT00877396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
Study: NCT04095091

Intervention type: DEVICE
Intervention: 4D Planar US Transducer
Description: This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.

Intervention type: DEVICE
Intervention: 4D Planar US Transducer
Description: This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
Study: NCT01799551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ca CBT
Description: Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
Study: NCT00788710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663) 120 mg
Description: 120 mg of etoricoxib (MK0663) for a total of 5 days
Study: NCT02631863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with illumination
Study: NCT04260737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid for Men with Localized Prostate Cancer
Description: The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
Study: NCT00788710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets once daily on Days 1-5. Total treatment is 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663) 90 mg
Description: 90 mg of etoricoxib (MK0663) for a total of 5 days
Study: NCT04238169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg once every three weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 30-50Gy/5F（2-4 lesions）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 30-50Gy/5F（2-4 lesions）
Study: NCT03404297

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Locally sourced compression therapy
Description: The dressing is made up of a zinc oxide impregnated compression wrapping

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locally sourced compression therapy
Description: The dressing is made up of a zinc oxide impregnated compression wrapping
Study: NCT02343198

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Custom-built research muscle stimulator
Description: Muscle stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-built research muscle stimulator
Description: Muscle stimulator
Study: NCT04508491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm control
Description: Rhythm control with medications or any procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Rate control
Study: NCT00005834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Arms 1 and 2: 40 mg/d PO days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Arms 1 and 2: 40 mg/d PO days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Arm 2: 800 mg/d (max dose) PO daily
Study: NCT01990859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT01399320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate
Description: excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
Study: NCT02709876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
Study: NCT01140061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Patch
Description: MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Cream
Description: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Cream
Description: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Cream
Description: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Cream
Description: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
Study: NCT02952027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use-recording, patient-reminder alarm for incentive spirometry
Study: NCT00056472

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: 10-20mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-20mg/day
Study: NCT01140061

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plain patch
Description: Plain patch containing no MK-0873 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain patch
Description: Plain patch containing no MK-0873 or placebo
Study: NCT04313478

Intervention type: BEHAVIORAL
Intervention: Low Birth Weight and Normal Weight infants
Description: This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.

Intervention type: BEHAVIORAL
Intervention: Low Birth Weight and Normal Weight infants
Description: This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
Study: NCT04374955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Activia Probiotics Shot
Description: The product contains Actiregularis - at least 2x106 cfu / g.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine care of the hospital will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care of the hospital will be provided.
Study: NCT04957056

Intervention type: PROCEDURE
Intervention: Hospitalization
Description: Hospitalization
Study: NCT00459654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
Study: NCT01078844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: memantine 5-20 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike placebo
Study: NCT00562562

Intervention type: OTHER
Group type: OTHER
Intervention: osteopathic manipulative treatment
Description: Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
Study: NCT01439373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Active Investigational Drug
Study: NCT00056472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 150-200mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet that ressembles sertraline but contains no medication
Study: NCT01439373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Active Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Standard of Care drug
Study: NCT04294511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Description: camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
Study: NCT03535428

Intervention type: DIAGNOSTIC_TEST
Intervention: VENOUS exploration
Description: venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
Study: NCT01854905

Intervention type: OTHER
Intervention: No Treatment
Description: Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
Study: NCT00316758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses bid
Study: NCT01439373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Standard of Care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Standard of Care drug
Study: NCT03911440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Study: NCT01724021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Standard chemotherapy
Study: NCT01439373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Standard of Care drug
Study: NCT00316758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, in patients who were in study BM18249
Study: NCT00425204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (ABX-EGF)
Description: Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
Study: NCT01439373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2336805 Matching Placebo
Description: Placebo of Investigational Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2336805 Matching Placebo
Description: Placebo of Investigational Drug
Study: NCT00830180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NGF AB
Description: Solution for injection, 10 mg, one injection/8 weeks
Study: NCT02868047

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Description: Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Description: Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
Study: NCT04305561

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast-enhanced ultrasound
Description: Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma).
Study: NCT01796821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 1.0 % SM
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 2.3% SM
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study: NCT03297125

Intervention type: DEVICE
Intervention: Standard Magnetic Resonance Imaging (MRI)
Description: Standard MRI.

Intervention type: DEVICE
Intervention: Advanced MRI.
Description: Perfusion and diffusion MRI.